Articles: 30.03 March 2019

The rising tide of biological therapy

In this editorial, Rupert Payne, Consultant Editor for Prescriber, discusses the increasing use of biological therapy

More details...

Recognition and management of systemic lupus erythematosus

Early recognition of the signs and symptoms of systemic lupus erythematosus (SLE) is important in order to expedite diagnosis, referral and treatment. This article discusses the wide spectrum of clinical manifestations of SLE, the treatment options available and the GP’s role in management

More details...

Emerging UK infections: identifying new threats early

Predicting which new and emerging pathogens will pose a threat to the UK population can be difficult. This article discusses the steps Public Health England and other government agencies are taking to identify new threats and protect the public against emerging infections

More details...

Cardiovascular risk prediction for primary prevention

Risk prediction tools such as QRISK identify those at higher risk of heart attack and stroke, based on traditional and emerging cardiovascular risk factors, with a view to primary prevention, eg with statins. This article considers how this important aspect of public health management can be optimised

More details...

Implementing the EU Falsified Medicines Directive

The European Union’s Falsified Medicines Directive, which came into force on 9 February, has laid down rigorous rules for pharmaceutical companies and pharmacists to follow in a bid to eradicate the pernicious impact of fake drugs infiltrating the legal supply chain. Joy Ogden reports on the progress so far

More details...

Summary of the BSR biological DMARD safety guidelines

The British Society for Rheumatology (BSR) recently published new evidence-based guidelines on the safe prescribing of biological DMARDs for inflammatory arthritis. This article provides a summary of their recommendations on screening, monitoring and considering co-morbidities prior to and during treatment

More details...

Erenumab: a monoclonal antibody for migraine prophylaxis

Erenumab (Aimovig) is a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor that has been licensed for the prophylaxis of migraine in adults who have at least four migraine days per month. This article discusses its efficacy, adverse effects and place in therapy

More details...

Web design and marketing agency Leamington Spa